Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition

Cell Death and Disease

Volumn 3, Issue 6, 2012, Pages

  Jin, H O ^a   Hong, S E ^a,b   Woo, S H ^a   Lee, J H ^c   Choe, T B ^d   Kim, E K ^e   Noh, W C ^e   Lee, J K ^e   Hong, S I ^a,e   Kim, J I ^b   Park, I C ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Seoul Women University   (South Korea)

^c Catholic Kwandong University   (South Korea)

^d Konkuk University   (South Korea)

^e Korea Cancer Center Hospital   (South Korea)

Author keywords

AMPK; cisplatin; mTOR; p21Waf1 CIP1; Twist1

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN; PROTEIN MCL 1; PROTEIN TWIST1; S6 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MTOR PROTEIN, HUMAN; NUCLEAR PROTEIN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; DOWN REGULATION; DRUG INDICATION; DRUG MECHANISM; DRUG SENSITIZATION; ENZYME INHIBITION; ENZYME REGULATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; APOPTOSIS; DRUG ANTAGONISM; GENE SILENCING; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MAMMALIA;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; GENE SILENCING; HUMANS; LUNG NEOPLASMS; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TWIST TRANSCRIPTION FACTOR;

EID: 84863465405     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.63     Document Type: Article

References (33)

1. Sanders HR, Albitar M. Somatic mutations of signaling genes in non-small-cell lung cancer. Cancer Genet Cytogenet 2010; 203: 7-15.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2009; 360: 1917.
3. Nishio K, Nakamura T, Koh Y, Suzuki T, Fukumoto H, Saijo N. Drug resistance in lung cancer. Curr Opin Oncol 1999; 11: 109-115.
4. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 307-318.
5. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010; 18: 39-51.
6. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005; 433: 477-480.
7. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430.
8. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
9. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
10. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-428.
11. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939.
12. Kang Y, Massagué J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004; 118: 277-279.
13. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 2004; 23: 474-482.
14. Nakashima H, Hashimoto N, Aoyama D, Kohnoh T, Sakamoto K, Kusunose M et al. Involvement of the transcription factor twist in phenotype alteration through epithelialmesenchymal transition in lung cancer cells. Mol Carcinog 2012; 51: 400-410.
15. Li J, Zhou BP. Activation of b-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 2011; 11: 49.
16. Cheng GZ, Zhang W, Wang LH. Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 2008; 68: 957-960.
17. Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 2010; 29: 4947-4958.
18. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2011; 30: 1963-1968.
19. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 2008; 105: 10853-10858.
20. Chan S. Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer 2004; 91: 1420-1424.
21. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: Implications for cancer and anticancer therapy. Br J Cancer 2006; 94: 195-199.
22. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 2010; 120: 3594-3605.
23. Zhuo WL, Wang Y, Zhuo XL, Zhang YS, Chen ZT. Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res Commun 2008; 369: 1098-1102.
24. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003; 17: 1475-1486.
25. Wangpaichitr M, Wu C, You M, Kuo MT, Feun L, Lampidis T et al. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-Apoptotic proteins. Eur J Pharmacol 2008; 591: 124-127.
26. Chen W, Bai L, Wang X, Xu S, Belinsky SA, Lin Y. Acquired activation of the Akt/ cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol 2010; 77: 416-423.
27. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331-342.
28. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 28: 332-337.
29. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37: 19-24.
30. Fan S, Chang JK, Smith ML, Duba D, Fornace AJ Jr, O'Connor PM. Cells lacking CIP1/ WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 1997; 14: 2127-2136.
31. Gorospe M, Wang X, Holbrook NJ. Functional role of p21 during the cellular response to stress. Gene Expr 1999; 7: 377-385.
32. Jin HO, Seo SK, Kim YS, Woo SH, Lee KH, Yi JY et al. TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1. Oncogene 2011; 30: 3792-3801.
33. Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF et al. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: Inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 2007; 109: 3031-3041.